Instituto Perdizes - HC/IPer
URI Permanente desta comunidade
Instituto Perdizes (IPer): Inaugurado em 8 de novembro de 2022. Construído no mesmo local onde funcionou por mais de 40 anos o Hospital Auxiliar de Cotoxó (HAC 1971-2011), espaço que precisou ser totalmente modernizado para abrigar os três blocos e 200 leitos de internação, distribuídos em área construída de aproximadamente 23 mil m². O primeiro bloco é um centro para tratamento de doenças relacionadas ao uso de álcool e drogas, com ambulatório, hospital-dia e unidade de internação; o segundo contempla a unidade de transição de cuidados, oferecendo assistência médica e multiprofissional a pacientes agudos não críticos, ensino médico de alunos de graduação e pós-graduação e desenvolvimento de pesquisas na área; e o terceiro, prevê um centro de tecnologia e inovação para maior eficiência do sistema de saúde. A Unidade de Transição de Cuidados, dotada com 120 leitos de internação, distribuídos em 60 enfermarias com 2 leitos cada, atende pacientes provenientes dos demais Institutos do HCFMUSP que necessitam de assistência em regime de internação para a efetiva transição de cuidados, visando a alta hospitalar e assim garantindo o acesso de leitos de alta complexidade desses Institutos para outros pacientes usuários do SUS que deles de fato necessitam. O Centro de Álcool e Drogas | Unidade especializada voltada à assistência, ao ensino, à pesquisa e ao desenvolvimento de metodologias de tratamento, reabilitação psicossocial e reinserção social às pessoas que fazem uso prejudicial de substâncias psicoativas (SPA). Estas atividades são distribuídas nas modalidades de internação hospitalar, assistência em hospital-dia e assistência ambulatorial. A Unidade de Internação atende pacientes provenientes, preferencialmente, do Instituto de Psiquiatria, dos demais Institutos e unidades do HCFMUSP e do Sistema Informatizado de Regulação do Estado de São Paulo (SIRESP) que necessitam de assistência médica global (psiquiátrica e clínica) em regime de internação. A Unidade Ambulatorial do Centro de Álcool e Drogas atende pacientes referenciados pelo SIRESP, pelo Instituto de Psiquiatria (IPq) e demais unidades que integram o HCFMUSP, bem como pacientes egressos da Internação e do Hospital-Dia do Centro de Álcool e Drogas do próprio Instituto Perdizes.
Site oficial: https://www.hc.fm.usp.br/hc/unidades/instituto-perdizes
Site oficial: https://www.hc.fm.usp.br/hc/unidades/instituto-perdizes
Índice h
Scopus: 2
Navegar
Coleções desta Comunidade
- Instituto Perdizes - HC/IPer
- Instituto Perdizes - HC/IPer
- Instituto Perdizes - HC/IPer
Submissões Recentes
Psychopharmacology of smoking cessation medications: focus on patients with mental health disorders
(2023) CASTALDELLI-MAIA, Joao Mauricio; OLIVEIRA, Victoria Camargos de; IRBER, Flavia Mariana; BLAAS, Israel K.; ANGERVILLE, Bernard; MARTINS-DA-SILVA, Anderson Sousa; GIMENES, Gislaine Koch; CAMPOS, Marcela Waisman; TORALES, Julio; VENTRIGLIO, Antonio; GUILLOIS, Carine; OUAZZANI, Houria El; GAZAIX, Lena; FAVRE, Pascal; DERVAUX, Alain; APTER, Gisele
The adverse effects of smoking cessation in individuals with mental health disorders have been a point of concern, and progress in the development of treatment has been slow. The primary first-line treatments for smoking cessation are Nicotine Replacement Therapy, Bupropion, Varenicline, and behavioural support. Nortriptyline and Clonidine are second-line treatments used when the first-line treatments are not effective or are contraindicated. Smoking cessation medications have been shown to be effective in reducing nicotine cravings and withdrawal symptoms and promoting smoking cessation among patients living with mental disorders. However, these medications may have implications for patients' mental health and need to be monitored closely. The efficacy and side effects of these medications may vary depending on the patient's psychiatric condition, medication regimen, substance use, or medical comorbidities. The purpose of this review is to synthesise the pharmacokinetics, pharmacodynamics, therapeutic effects, adverse effects, and pharmacological interactions of first- and second-line smoking cessation drugs, with an emphasis on patients suffering from mental illnesses. Careful consideration of the risks and benefits of using smoking cessation medications is necessary, and treatment plans must be tailored to individual patients' needs. Monitoring symptoms and medication regimens is essential to ensure optimal treatment outcomes.
Women and MDMA: particularities of gender and sex
(2023) CAREZZATO, Fabio; ARRUDA, Ilana Falcao de; FIGUEIREDO, Caio Petrus Monteiro; CASTALDELLI-MAIA, Joao Mauricio
This comprehensive review delves into the intricate interplay between gender/sex and MDMA use, drawing upon recent evidence. It explores how girls, as a means of coping with negative emotions, often resort to drug use, while boys primarily initiate drug use due to peer pressure or sensation-seeking tendencies. Women, frequently having endured traumatic life events, may turn to MDMA as a form of self-medication. Notably, women face an elevated risk of contracting sexually transmitted infections due to their altered mental states and diminished condom use during MDMA consumption. Additionally, females exhibit heightened sensitivity to the subjective effects of MDMA, consistently reporting heightened anxiety, adverse effects, and negative side effects. While women may have a higher susceptibility to hyponatremia, intriguingly, they appear to be less vulnerable to MDMA-induced hyperthermia. Although limited, available data suggest that prenatal MDMA exposure could lead to motor delays in infants, necessitating further research to unravel the potential cognitive effects. Furthermore, MDMA-assisted psychotherapy holds immense promise for addressing post-traumatic stress disorder (PTSD) among female subgroups. These pronounced gender and sex disparities in MDMA use and its effects underscore the pressing need for additional research to develop tailored, effective, and safe treatment approaches that account for these fundamental factors.
Performance measures for alcohol and other drugs services: a commentary
(2023) AMARAL, Ricardo Abrantes do
Alcohol and other drugs treatment includes a wide range of service and personal characteristics, along with expected and unexpected barriers to treatment. To capture the benefits and the gaps of a designed treatment, one needs to consider process-of-care and outcome measurements. Process-of-care measures are mainly developments of the rationale proposed by The Washington Circle and capture all variants in the process-of-care as proportions. Outcome measures are strongly related to different concepts of recovery and described as simple yes/no answers type to wide levels of response, such as in Likert-type scales. According to the studies collected here, more realistic periods of data-collection for process-of-care measures and a more reliable format to capture outcome particularities should be designed.
Bariatric surgery and it influence in alcohol consumption-differences before and after surgery, a systematic review and meta-analysis
(2023) VIDES, Mariana Capelo; OLIVEIRA, Mariana Campello de; LASSI, Dangela Layne Silva; MALBERGIER, Andre; FLORIO, Ligia; PERICO, Cintia de Azevedo-Marques; AMARAL, Ricardo Abrantes do; TORALES, Julio; VENTRIGLIO, Antonio; NEGRAO, Andre Brooking; CASTALDELLI-MAIA, Joao Mauricio
BackgroundThrough new publications on the subject, the main goal of this article is to seek a change in the pattern of alcohol use before and after bariatric surgery.MethodsWe searched the National Library of Medicine, CINAHL, and PsycINFO databases. We included original articles regarding alcohol consumption before and after bariatric surgery to conduct the systematic review.ResultsOur systematic review, which included 18 articles, yielded mixed results. Meta-analysis of six articles did not reveal statistically significant differences in alcohol use behaviours before and one year after bariatric surgery. However, throughout the perspective of follow-up after bariatric surgery, nine out of the twelve articles showed improvement in the pattern of alcohol consumption when evaluated up to two years after the end of the surgical period, and four out of the five articles with monitoring beyond two years showed worsening in consumption, compared to pre-surgery alcohol use behaviours.ConclusionsConclusions about the relationship between alcohol consumption and bariatric surgery are challenging primarily because of the variety of the methods used and the alcohol consumption measures. Despite that, our research pointed to an increased risk of alcohol use disorders two years after bariatric surgery.
BRAF-testing medical education needs in Latin America
(2023) CASTALDELLI-MAIA, J. M.; GIMENES, G. K.; PERROTTE, G.; GONZALEZ, S.; OKASSOVA, A.; MALVIDO, K.; TORALES, J.